About Our Program

As a research center embedded within Kaiser Permanente’s large and dynamic health care system, our investigators have a unique opportunity to apply scientific expertise to real-world clinical problems, translate findings into practice, and share what we learn with the broader community.

Featured Scientist

Dr. Gary Buchschacher
Gary L. Buchschacher Jr., MD, PhD
Principal Investigator
Los Angeles
Medical Oncology
Clinical.Trials@kp.org

Dr. Gary Buchschacher is the director of the Cancer Clinical Trials Access Program. He coordinates and leads the program’s activities and acts as principal investigator for numerous studies. He is the site PI for the Kaiser Permanente Los Angeles Medical Center and a member of its Oncology Steering Committee.

Dr. Buchschacher is the medical oncology lead for the Southern California Permanente Medical Group’s Gastrointestinal Cancer Subcommittee and a member of the Regional Cancer ...

Featured Video

Advancing treatments through clinical trials

Over the years, clinical trials have led to amazing advances in treatment—even cures—for devastating illnesses. William Towner, MD, FACP, FIDSA, regional physician director for clinical trials, describes how trials at Kaiser Permanente contribute to the development of more effective and safer treatments for diseases such as HIV, hepatitis C, cancer, and more. (2:15)

News

Featured Image of News Story Titled: Blended prenatal care shows similar outcomes with fewer in-person visits

Blended prenatal care shows similar outcomes with fewer in-person visits

A blended prenatal care model that combined virtual and in-person visits was associated with similar birth outcomes compared with traditional in-person care, according to new Kaiser Permanente research. The study was published November 11, 2026, in Pregnancy. The study, conducted within Kaiser Permanente Southern California and Kaiser Permanente Northwest, compared pregnant patients who received care ...

Good news for people newly diagnosed with MOGAD: Study finds low relapse risk

People newly diagnosed with myelin oligodendrocyte glycoprotein antibody-associated disease, or MOGAD, generally had a low risk of relapse and lasting disability, according to a Kaiser Permanente study. Researchers from Kaiser Permanente in Southern California followed 69 children and adults diagnosed at their first MOGAD attack and found that more than 80% fully recovered, while just ...

Ultraprocessed foods linked to body fat gain in children

Children who ate more ultraprocessed foods showed stronger activity in a part of the brain involved in reward, and that brain response was linked to greater gains in body fat over the following year, a new study found. The study — published October 2026 in JAMA Network Open — followed 46 children ages 7 to ...

No increased stroke risk found after COVID-19 and flu vaccinations

A large multisite study found that bivalent mRNA COVID-19 vaccination, flu vaccination, and same-day administration of both vaccines were not associated with an increased risk of first-ever ischemic stroke. “This study found no evidence of an increased risk of ischemic stroke following bivalent COVID-19 vaccination, influenza vaccination, or receiving both vaccines on the same day,” ...

RSV vaccine protects older adults for at least 3 seasons

An RSV vaccine continued to protect adults aged 60 and older against RSV-related hospitalization and emergency department visits for at least 3 seasons after vaccination, according to a new study by Kaiser Permanente in Southern California. RSV, or respiratory syncytial virus, is a common respiratory virus that can cause serious illness, hospitalization, and even death ...

Featured Division

Epidemiologic Research

Investigators with the Division of Epidemiologic Research apply rigorous research methods to address important health questions that have the potential to change clinical practice and health care delivery. The division’s research portfolio spans the care continuum, from etiology and prevention to survivorship and quality of life.

Division investigators have expertise in traditional epidemiologic studies, post-marketing safety and effectiveness studies, and outcomes research. Current research areas include cancer, cardiovascular disease, COVID-19, diabetes, infectious disease, molecular epidemiology, orthopedics and bone health, perinatal health, pharmacoepidemiology, and vaccines.